Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for I-Mab Sponsored ADR (IMAB : NSDQ)

• Company Description    I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China. Number of Employees: 32

• Price / Volume Information    Yesterday's Closing Price: $2.16 Daily Weekly Monthly 20 Day Moving Average: 544,763 shares Shares Outstanding: 81.66 (millions) Market Capitalization: $176.39 (millions) Beta: 1.40 52 Week High: $3.08 52 Week Low: $0.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.30% -11.95% 12 Week 153.43% 120.73% Year To Date 154.12% 137.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2440 RESEARCH BLVD SUITE 400 - ROCKVILLE,MD 20850 USA ph: 301-670-2800 fax: - ir@imabbio.com https://ir.i-mabbiopharma.com

• General Corporate Information    Officers Xi-Yong (Sean) Fu - Chief Executive Officer and Director Wei Fu - Chairperson of the Board of Directors Joseph Skelton - Chief Financial Officer Lielie Zhang - Director Chun Kwok Alan Au - Director Peer Information I-Mab Sponsored ADR (CORR.) I-Mab Sponsored ADR (RSPI) I-Mab Sponsored ADR (CGXP) I-Mab Sponsored ADR (BGEN) I-Mab Sponsored ADR (GTBP) I-Mab Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44975P103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/27/25 Share - Related Items Shares Outstanding: 81.66 Most Recent Split Date: (:1) Beta: 1.40 Market Capitalization: $176.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/27/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.89 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -19.81 12/31/24 - -29.62 ROA 06/30/25 - - 03/31/25 - -18.63 12/31/24 - -27.78 Current Ratio 06/30/25 - - 03/31/25 - 22.35 12/31/24 - 20.90 Quick Ratio 06/30/25 - - 03/31/25 - 22.35 12/31/24 - 20.90 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.43 12/31/24 - 2.47 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©